CytRx Corporation (CYTR)

OTCMKTS: CYTR · Delayed Price · USD
+0.0067 (7.19%)
Jul 1, 2022 4:00 PM - Market closed

Company Description

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases.

It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor.

The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor.

It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates.

CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

CytRx Corporation
Country United States
Founded 1985
IPO Date Nov 10, 1986
Industry Biotechnology
Sector Health Care
Employees 3
CEO Steven Kriegsman

Contact Details

11726 San Vicente Blvd Ste 650
Los Angeles, California 90049-5079
United States
Phone 310 826 5648

Stock Details

Ticker Symbol CYTR
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0000799698
CUSIP Number 232828301
ISIN Number US2328286081
Employer ID 58-1642740
SIC Code 2836

Key Executives

Name Position
John Y. Caloz Chief Financial Officer, Treasurer and Senior Vice President
Dr. Stephen Snowdy Ph.D. Chief Executive Officer
Molly Carey Poarch Global and U.S. Head of Corporate Communications
Molly Painter President of USA and Head of Launch and Commercial Operations
Terri Stevens Chief Business Officer
Cristina Newman Corporate Secretary
Dr. Felix Kratz Ph.D. Senior Vice President, Drug Development

Latest SEC Filings

Date Type Title
Jun 16, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 16, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 16, 2022 DEF 14A Other definitive proxy statements
Jun 3, 2022 PRE 14A Other preliminary proxy statements
Jun 2, 2022 8-K Current report
May 19, 2022 8-K Current report
May 19, 2022 8-A12G Registration of securities [Section 12(g)]
May 12, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
Mar 28, 2022 EFFECT Notice of Effectiveness
Mar 25, 2022 424B3 Prospectus [Rule 424(b)(3)]